The global single-photon emission computed tomography (SPECT) market is set for robust growth over the next decade, with its valuation projected to rise from USD 2.45 billion in 2022 to approximately USD 4.76 billion by 2032. Expanding at a compound annual growth rate (CAGR) of 6.9% during this period, this growth highlights the increasing adoption of SPECT imaging as a critical diagnostic tool in healthcare.
The rising prevalence of cardiovascular diseases, neurological disorders, and cancer is fueling demand for advanced diagnostic solutions, positioning SPECT systems as an essential component of modern medical imaging. These technologies enable early detection and monitoring of various conditions, improving patient outcomes and treatment effectiveness.
Several factors are driving market expansion, including advancements in SPECT imaging technology, integration with hybrid systems like SPECT/CT, and increasing investments in healthcare infrastructure globally. Additionally, the growing awareness of personalized medicine and the need for precise diagnostics are further bolstering demand.
North America continues to dominate the SPECT market, attributed to the region’s advanced healthcare infrastructure, high disease prevalence, and strong R&D investments. However, the Asia-Pacific region is expected to witness significant growth during the forecast period, driven by rising healthcare expenditures, growing awareness of advanced imaging technologies, and expanding access to healthcare in emerging economies.
Market Dynamics
- Growth Drivers:
- The rising prevalence of cardiovascular diseases and cancer is a significant factor driving the demand for SPECT technology. As these conditions become more common, the need for effective diagnostic imaging solutions increases.
- Advancements in SPECT technology, including the development of hybrid imaging systems, are enhancing diagnostic capabilities and contributing to market growth.
- Market Segmentation:
- The market is primarily segmented by application, with cardiology being the leading segment due to its critical role in diagnosing heart-related issues.
- Other applications include oncology and neurology, which are also experiencing growth due to increasing awareness and advancements in imaging techniques.
Regional Insights
- North America dominates the SPECT market, driven by a well-established healthcare infrastructure, high prevalence of cardiac and cancer cases, and significant investments in advanced imaging technologies.
- Europe also holds a substantial share, supported by ongoing investments in diagnostic centers and increasing healthcare expenditure.
Competitive Landscape
To establish a dominant position in the market, major players in the single-photon emission computed tomography market are aggressively concentrating on partnerships, product launches, and expansion. For instance,
- In November 2020, GE Healthcare announced its acquisition of Prismatic Sensors AB, a Swedish startup specializing in photon-counting detectors, signifying the company’s continued investment in photon-counting CT technology.
- In May 2022, Mediso Ltd announced the acquisition of Bartec Technologies Ltd, UK based company specializing in the supply, installation, and support of Nuclear Medicine and Molecular Imaging equipment and accessories.
Key Companies Profiled
Bruker Corp.; DDD-Diagnostic AS; Digmed Corp.; General Electric Co.; Mediso Ltd.; MiE GmbH; MILabs BV; Siemens Healthineers AG; Spectrum Dynamics Medical Inc.; GE Healthcare; CardiArc; Beijing Hamamatsu Photon Techniques INC.; SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.; PNPMed; NuCare Inc.
Full Report Revealed
Key Market Segments Covered in Single-photon Emission Computed Tomography Industry Research
By Product:
- Single Imaging Gamma Cameras
- SPECT/CT
By Application:
- Cardiology
- Oncology
- Neurology
- Others
By End User:
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube